» Articles » PMID: 21805942

Resource Use and Costs of End-of-Life/palliative Care: Ontario Adult Cancer Patients Dying During 2002 and 2003

Overview
Journal J Palliat Care
Specialty Critical Care
Date 2011 Aug 3
PMID 21805942
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study is to estimate the direct medical cost of end-of-life and palliative (EOL/PAL) care for cancer patients during the last six months of their lives--or, during the period from diagnosis to death, if briefer--in 2002 and 2003, in Ontario, Canada. A linkage of cancer registry and administrative data is used to determine the costs of health care resources used during the EOL/PAL care period. Costs are analyzed by cancer diagnosis, location of death, and type of service. The total Ontario Ministry of Health-funded cost of EOL/PAL care for cancer patients is estimated to be about CAD$544 million per year, with an average per patient cost of about $25,000 in 2002-2003. Our results suggest that acute care consumes 75 percent of EOL/PAL funding and that only a small proportion of health care services used by EOL/PAL care cancer patients is likely to be formal palliative care.

Citing Articles

Methodologies and characteristics of studies investigating the cost of the palliative phase of cancer: a systematic review.

Chechirlian K, Messin M, Dantigny R, Economos G, Tete C, Perceau-Chambard E Support Care Cancer. 2025; 33(2):126.

PMID: 39873852 DOI: 10.1007/s00520-025-09150-0.


Costs of Palliative Care in Oncological and Non-Oncological Patients with Different Types of Ambulatory-Based Attention: Cost-Study Protocol.

Perea-Bello A, Trapero-Bertran M, Dursteler C Diseases. 2024; 12(10).

PMID: 39452486 PMC: 11507158. DOI: 10.3390/diseases12100243.


The Challenges of Advance Care Planning for Acute Care Registered Nurses.

Rietze L, Stajduhar K, Purkis M, Cloutier D Can J Nurs Res. 2024; 56(3):293-302.

PMID: 38576275 PMC: 11308282. DOI: 10.1177/08445621241244532.


Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review.

Perea-Bello A, Trapero-Bertran M, Dursteler C Pharmacoeconomics. 2023; 42(3):301-318.

PMID: 38151673 PMC: 10861396. DOI: 10.1007/s40273-023-01336-w.


The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.

Hillis C, Vicente C, Ball G Pharmacoeconomics. 2022; 40(9):917-928.

PMID: 35844002 DOI: 10.1007/s40273-022-01169-z.